ATE480250T1 - Neue trp2-isoform mit cytotoxischen t-lymphozyten-epitopen mit hla-a2-restriktion - Google Patents

Neue trp2-isoform mit cytotoxischen t-lymphozyten-epitopen mit hla-a2-restriktion

Info

Publication number: ATE480250T1
Authority: AT; Austria
Prior art keywords: trp2; new; protein; isoform; hla
Prior art date: 2001-03-19

Application number

AT02753623T

Other languages

English (en)

Inventor

Hung Khong

Steven Rosenberg

Original Assignee

Us Gov Health & Human Serv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-19

Filing date

2002-03-15

Publication date

2010-09-15

2002-03-15 Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv

2010-09-15 Application granted granted Critical

2010-09-15 Publication of ATE480250T1 publication Critical patent/ATE480250T1/de

Links

102100031413 L-dopachrome tautomerase Human genes 0.000 title abstract 3
LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 title abstract 2
101710093778 L-dopachrome tautomerase Proteins 0.000 title abstract 2
102000025850 HLA-A2 Antigen Human genes 0.000 title 1
108010074032 HLA-A2 Antigen Proteins 0.000 title 1
102000001708 Protein Isoforms Human genes 0.000 title 1
108010029485 Protein Isoforms Proteins 0.000 title 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 title 1
102000004169 proteins and genes Human genes 0.000 abstract 3
108090000623 proteins and genes Proteins 0.000 abstract 3
206010028980 Neoplasm Diseases 0.000 abstract 2
241000124008 Mammalia Species 0.000 abstract 1
102000007079 Peptide Fragments Human genes 0.000 abstract 1
108010033276 Peptide Fragments Proteins 0.000 abstract 1
210000001744 T-lymphocyte Anatomy 0.000 abstract 1
239000000427 antigen Substances 0.000 abstract 1
102000036639 antigens Human genes 0.000 abstract 1
108091007433 antigens Proteins 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
238000001514 detection method Methods 0.000 abstract 1
108010051081 dopachrome isomerase Proteins 0.000 abstract 1
230000028993 immune response Effects 0.000 abstract 1
201000001441 melanoma Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
150000007523 nucleic acids Chemical class 0.000 abstract 1
230000003389 potentiating effect Effects 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464456—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464488—NY-ESO
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464491—Melan-A/MART
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464492—Glycoprotein 100 [Gp100]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Chemical & Material Sciences (AREA)
Cell Biology (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Mycology (AREA)
Organic Chemistry (AREA)
Toxicology (AREA)
Biotechnology (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Gastroenterology & Hepatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hospice & Palliative Care (AREA)
Zoology (AREA)
Biophysics (AREA)
Tropical Medicine & Parasitology (AREA)
Genetics & Genomics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

AT02753623T 2001-03-19 2002-03-15 Neue trp2-isoform mit cytotoxischen t-lymphozyten-epitopen mit hla-a2-restriktion ATE480250T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US27710801P	2001-03-19	2001-03-19
PCT/US2002/007698 WO2002074788A2 (en)	2001-03-19	2002-03-15	TRP2 ISOFORM TRP2-6b CONTAINING HLA-A2-RESTRICTED EPITOPES

Publications (1)

Publication Number	Publication Date
ATE480250T1 true ATE480250T1 (de)	2010-09-15

Family

ID=23059437

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02753623T ATE480250T1 (de)	2001-03-19	2002-03-15	Neue trp2-isoform mit cytotoxischen t-lymphozyten-epitopen mit hla-a2-restriktion

Country Status (7)

Country	Link
US (1)	US7476535B2 (de)
EP (1)	EP1377304B1 (de)
AT (1)	ATE480250T1 (de)
AU (1)	AU2002336244A1 (de)
CA (1)	CA2441225C (de)
DE (1)	DE60237588D1 (de)
WO (1)	WO2002074788A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1555271A1 (de) *	2004-01-15	2005-07-20	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Peptide zur Diagnose und Behandlung von TRP-2+ und/oder TRP-1+ Tumoren

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU1598500A (en) *	1998-10-26	2000-05-15	Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The	Hla-a2 and hla-dr specific peptide epitopes from the melanoma antigen trp2

2002
- 2002-03-15 US US10/468,665 patent/US7476535B2/en not_active Expired - Fee Related
- 2002-03-15 DE DE60237588T patent/DE60237588D1/de not_active Expired - Lifetime
- 2002-03-15 AU AU2002336244A patent/AU2002336244A1/en not_active Abandoned
- 2002-03-15 AT AT02753623T patent/ATE480250T1/de not_active IP Right Cessation
- 2002-03-15 EP EP02753623A patent/EP1377304B1/de not_active Expired - Lifetime
- 2002-03-15 CA CA2441225A patent/CA2441225C/en not_active Expired - Fee Related
- 2002-03-15 WO PCT/US2002/007698 patent/WO2002074788A2/en not_active Application Discontinuation

Also Published As

Publication number	Publication date
DE60237588D1 (de)	2010-10-21
CA2441225A1 (en)	2002-09-26
EP1377304B1 (de)	2010-09-08
CA2441225C (en)	2011-07-26
WO2002074788A2 (en)	2002-09-26
WO2002074788A3 (en)	2003-10-30
US20040116667A1 (en)	2004-06-17
EP1377304A2 (de)	2004-01-07
EP1377304A4 (de)	2005-02-09
AU2002336244A1 (en)	2002-10-03
US7476535B2 (en)	2009-01-13

Legal Events

Date	Code	Title	Description
2011-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
WO2003045128A3 (en)	2006-04-06	SYNTHETIC IMMUNOGENIC BUT NON-DEPOSIT-FORMING POLYPEPTIDES AND PEPTIDES HOMOLOGOUS TO AMYLOID β, PRION PROTEIN, AMYLIN, α-SYNUCLEIN, OR POLYGLUTAMINE REPEATS FOR INDUCTION OF AN IMMUNE RESPONSE THERETO
CY1118443T1 (el)	2017-06-28	Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1118037T1 (el)	2017-05-17	Αντισωματα εναντι του αβητα και h χρηση τους
DK1461073T3 (da)	2010-03-29	Peptidagonister til prostataspecifikt antigen og anvendelser heraf
BG102983A (en)	2000-05-31	Extramembrane protein 106 polypeptide of moraxella catarrhalis, its gene sequence and application
ATE475675T1 (de)	2010-08-15	Verwendung prokariotischer pest-ähnlicher peptide zur verstärkung der immunogenität von antigenen
HUP0004639A2 (hu)	2001-04-28	Chlamydia fehérje, génszekvencia és ezek alkalmazása
DK1129190T3 (da)	2007-09-24	Human TSLP DNA og polypeptider
DK1265914T3 (da)	2008-03-10	WNT-1-relaterede polypeptider og nukleinsyrer, der koder for samme
ATE338121T1 (de)	2006-09-15	Von muc-1 abgeleitete peptide
DE69736306D1 (de)	2006-08-17	Rezeptor von dendritischen zellen.
Vichier‐Guerre et al.	2003	Induction of carbohydrate‐specific antibodies in HLA‐DR transgenic mice by a synthetic glycopeptide: a potential anti cancer vaccine for human use
ATE267213T1 (de)	2004-06-15	Peptide, die agonisten oder antagonisten des karzinoembrionalen antigens (cea) sind
DE60322559D1 (de)	2008-09-11	Neue, mhc klasse ii assoziierte peptide
JPS6470498A (en)	1989-03-15	Synthetic peptide and antibody thereto
FR2692282B1 (fr)	1995-07-13	Clonage du gene codant pour la proteine gp28.5 de t. gondii; fragments peptidiques issus de ladite proteine et leurs applications.
EP0972054A4 (de)	2005-02-23	Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
EA200100395A1 (ru)	2001-10-22	Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием
ATE308559T1 (de)	2005-11-15	PEPTIDE, DIE CEA (ßCARCINOEMBRYONIC ANTIGENß) BINDEN
DE60237588D1 (de)	2010-10-21	Neue trp2-isoform mit cytotoxischen t-lymphozyten-epitopen mit hla-a2-restriktion
ATE509025T1 (de)	2011-05-15	ßMIT MHC-KLASSE-I-PEPTIDEPITOPEN KOVALENT VERKN PFTES MEMBRANVERANKERTES BETA2-MIKROGLOBULINß
NZ515041A (en)	2004-03-26	Nucleic acid immunization
AU2003239659A8 (en)	2003-10-13	Peptide epitopes common to antigens of the same multigene family
NO20005952D0 (no)	2000-11-24	Neisseria Meningitidis antigene polypeptider, korresponderende polynukleotider og beskyttende antistoffer
CO5280140A1 (es)	2003-05-30	Antigeno (c42) asociado a tumores